Literature DB >> 16216270

Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41.

John M Louis1, Carole A Bewley, Elena Gustchina, Annie Aniana, G Marius Clore.   

Abstract

Using a human non-immune phage library comprising more than 10(9) functional human antibody specificities in Fab format, we have been able to select a set of eight monoclonal Fabs targeted against diverse epitopes of the ectodomain of gp41 from HIV-1. The antigens used for panning the antibodies comprised two soluble, disulfide-linked, trimeric polypeptides derived from gp41, N(CCG)-gp41 and N35(CCG)-N13. The former comprises an exposed trimeric coiled-coil of the N-helices of gp41 fused in helical phase to the minimal thermostable ectodomain of gp41, while the latter comprises only the trimeric coiled-coil of N-helices. The selected Fabs were probed by Western blot analysis against four antigens: N(CCG)-gp41, N35CCG-N13, N34CCG (a smaller version of N35CCG-N13), and the minimal thermostable ectodomain core of gp41 in its six-helix bundle conformation (6-HB). Three classes of Fabs were found: class A (two Fabs) interact predominantly with the 6-HB; class B (four Fabs) interact with both the 6-HB and the internal trimeric coiled-coil of N-helices; and class C (two Fabs) interact specifically with the internal trimeric coiled-coil of N-helices. The IC50 values for the Fabs, expressed as bivalent mini-antibodies, ranged from 6 microg/ml to 60 microg/ml in a quantitative vaccinia virus-based reporter gene assay for HIV-1 envelope-mediated cell fusion using the envelope from the HIV-1 T tropic strain LAV. The two most potent fusion inhibitors belonged to class B. This panel of Fabs provides a set of useful probes for studying HIV-1 envelope-mediated cell fusion and may serve as a basis for developing Fab-based anti-HIV-1 therapeutics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216270     DOI: 10.1016/j.jmb.2005.09.044

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  20 in total

1.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Authors:  Elisabetta Bianchi; Joseph G Joyce; Michael D Miller; Adam C Finnefrock; Xiaoping Liang; Marco Finotto; Paolo Ingallinella; Philip McKenna; Michael Citron; Elizabeth Ottinger; Robert W Hepler; Renee Hrin; Deborah Nahas; Chengwei Wu; David Montefiori; John W Shiver; Antonello Pessi; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

2.  Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.

Authors:  Sara Crespillo; Ana Cámara-Artigas; Salvador Casares; Bertrand Morel; Eva S Cobos; Pedro L Mateo; Nicolas Mouz; Christophe E Martin; Marie G Roger; Raphaelle El Habib; Bin Su; Christiane Moog; Francisco Conejero-Lara
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

3.  Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.

Authors:  Elena Gustchina; John M Louis; Carole A Bewley; G Marius Clore
Journal:  J Mol Biol       Date:  2006-09-12       Impact factor: 5.469

4.  Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Authors:  Mei-Yun Zhang; Vidita Choudhry; Igor A Sidorov; Vladimir Tenev; Bang K Vu; Anil Choudhary; Hong Lu; Gabriela M Stiegler; Hermann W D Katinger; Shibo Jiang; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Immunol Methods       Date:  2006-10-16       Impact factor: 2.303

5.  Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.

Authors:  Elena Gustchina; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

6.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

7.  Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.

Authors:  Elena Gustchina; John M Louis; Christian Frisch; Francisco Ylera; Annette Lechner; Carole A Bewley; G Marius Clore
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

8.  A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains.

Authors:  Elena Gustchina; John M Louis; Son N Lam; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

9.  Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.

Authors:  Mei-Yun Zhang; Bang K Vu; Anil Choudhary; Hong Lu; Michael Humbert; Helena Ong; Munir Alam; Ruth M Ruprecht; Gerald Quinnan; Shibo Jiang; David C Montefiori; John R Mascola; Christopher C Broder; Barton F Haynes; Dimiter S Dimitrov
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.